User Settings
Article10.1161/circ.130.suppl_2.16378

Abstract 16378: Growth Differentiation Factor-15 Independently Predicts 2 Year Mortality in Patients With Acute Coronary Syndrome: Observations From the A to Z Trial

Ethan Kosova,James A. de Lemos,Petr Jarolı́m,Jianping Guo,Eugene Braunwald,Marc S. Sabatine+1 more-2014-11-25-Circulation
0

TL;DRAbstract

BACKGROUND: Growth Differentiation Factor-15 (GDF-15) is an inflammatory biomarker upregulated in the setting of myocardial stress that we and others have shown to have potential prognostic value in cardiovascular (CV) disease. However, any role for GDF-15 along with traditional CV risk factors and biomarkers in predicting long term mortality after ACS remains investigational. METHODS: We measured the plasma concentration of GDF-15 after stabilization of ACS in 4,179 patients (pts) presenting with UA/NSTEMI or STEMI enrolled in the A to Z Trial. Established, pre-specified cutoffs of GDF-15 (<1200, 1200-1800, and >1800 ng/L) were used for analysis. Outcomes were followed through the end of the study (median 2 years). RESULTS: Pts with GDF-15 >1800 ng/L had significantly higher 2 year mortality rates than those with levels of 1200-1800 or <1200 ng/L (14.8%, 9.7%, and 3.2%, respectively; P<0.001, Fig-1A). After adjusting for age, sex, hypertension, diabetes, renal function,

Chat with Paper

AI Agents for this Paper

BACKGROUND: Growth Differentiation Factor-15 (GDF-15) is an inflammatory biomarker upregulated in the setting of myocardial stress that we and others have shown to have potential prognostic value in cardiovascular (CV) disease. However, any role for GDF-15 along with traditional CV risk factors and biomarkers in predicting long term mortality after ACS remains investigational. METHODS: We measured the plasma concentration of GDF-15 after stabilization of ACS in 4,179 patients (pts) presenting with UA/NSTEMI or STEMI enrolled in the A to Z Trial. Established, pre-specified cutoffs of GDF-15 (<1200, 1200-1800, and >1800 ng/L) were used for analysis. Outcomes were followed through the end of the study (median 2 years). RESULTS: Pts with GDF-15 >1800 ng/L had significantly higher 2 year mortality rates than those with levels of 1200-1800 or <1200 ng/L (14.8%, 9.7%, and 3.2%, respectively; P<0.001, Fig-1A). After adjusting for age, sex, hypertension, diabetes, renal function,

Keywords

MedicineGDF15Internal medicineBiomarkerAcute coronary syndromeHeart failureCardiologyRenal function

Chat

Click to start Chat